Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
The risks and benefits of bedaquiline (BDQ) for treatment of drug-resistant tuberculosis (DR-TB) have not been firmly established. We aimed to assess the safety and efficacy of BDQ-containing regimens for the treatment of DR-TB as evidenced in available randomized controlled trials (RCTs). In this s...
Saved in:
Main Authors: | Muhammad Candragupta Jihwaprani, Yipeng Sun, Wahyu Choirur Rizky, Idris Sula, Nazmus Saquib |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | Pulmonary Medicine |
Online Access: | http://dx.doi.org/10.1155/2024/5542658 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pyrazinamide Resistance: A Major Cause of Switching Shorter to Longer Bedaquiline-based Regimens in Multidrug-resistant Tuberculosis Patients
by: Oki Nugraha Putra, et al.
Published: (2024-12-01) -
Formulation and optimisation of bedaquiline nanoemulsions for the potential treatment of multi drug resistant tuberculosis in paediatrics using quality by design
by: Taiwo Oreoluwa Ajayi, et al.
Published: (2024-12-01) -
Mice infected with M. tuberculosis with Rv0678 mutations still benefit from bedaquiline treatment
by: N. Lounis, et al.
Published: (2024-11-01) -
Initial Drug Regimen for Active Tuberculosis Cases in Montreal, 1995-1998
by: Paul Rivest, et al.
Published: (2001-01-01) -
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review
by: Denise Rossato Silva, et al.
Published: (2025-01-01)